Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Anti-inflammatory drug shows promise for frailty in older adults

NCT ID NCT05727384

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether clazakizumab, an anti-inflammatory drug, could improve walking speed and reduce disability in older adults with frailty. 29 participants aged 70 and older received either the drug or a placebo every 4 weeks for 24 weeks. Researchers measured walking speed, physical function, and blood markers of inflammation to see if the drug made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clazakizumab
What this could lead to
If it works, this could point toward a treatment that helps older adults with frailty walk faster and feel stronger by reducing inflammation.
What could go wrong
This is a small, early Phase 2 trial with only 29 participants, so results may not apply to everyone. The drug may not improve mobility or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

29 people

The number who actually took part.

Started

Aug 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Persons aged ≥ 70 years at time of randomization * Gait speed ≥ 0.44 m/sec to \< 1.0 m/sec or BMI ≥ 28 kg/m2 * IL-6 level ≥ 2.0 pg/ml but \< 30.0 pg/ml * Self-reported difficulty walking ¼ mile or climbing 10 steps * Self-reported ability to walk 400 meters (about 2-3 blocks), unassisted * Self-reported vaccinations for COVID-19, Influenza and pneumococcal pneumonia up to date per current CDC guidelines Exclusion Criteria: * Advanced neurologic disorder such as dementia, Parkinson's disease, amytrophic lateral sclerosis, or multiple sclerosis that would impact the ability to improve on functional assessments * Resident in a nursing home * Severe hearing or vision loss that would impair participant's ability to complete questionnaires or follow oral instructions, and which may limit feasibility of performing functional assessments * Acute infections (including but not limited to common cold virus, shingles virus, bronchitis, skin infection, urinary tract infection, tooth abscess) within 60 days of randomization * Chronic infection (including but not limited to): * History of active TB or evidence of latent TB based on a positive PPD skin test, positive Quantiferon TB-Gold test, or a history of old or latent TB on chest x-ray * History of Hepatitis B or Hepatitis C * Previous diagnosis of Human Immunodeficiency Virus (HIV) or Acquired ImmunoDeficiency Syndrome (AIDS) * Inflammatory or autoimmune disease (including but not limited to rheumatoid arthritis, lupus, or inflammatory bowel disease, such as ulcerative colitis or Crohn's disease) * Immunization with a live/attenuated vaccine within 2 months prior to randomization (e.g., viral: measles vaccine, mumps vaccine, rubella vaccine, live attenuated influenza vaccine, live attenuated chicken pox or shingles vaccine, smallpox vaccine, oral polio vaccine (Sabin), rotavirus vaccine, and yellow fever vaccine. Bacterial: BCG vaccine, oral typhoid vaccine and epidemic typhus vaccine) * Current use of chronic immune modulating medications such as corticosteroids, monoclonal antibodies, janus kinase inhibitors, calcineurin inhibitors, mTOR inhibitors, IMDH inhibitors, or biologics * Admitted for an overnight hospitalization in the last 6 months * Open-chest heart surgery (including, but not limited to, coronary artery bypass graft surgery or aortic valve surgery) in the past 6 months * Anticipating major surgery (including, but not limited to, chest, abdomen, or joint surgery) in the next 6 months * Deep vein thrombosis or pulmonary embolus in the past 6 months * Severe lung disease or heart disease that requires oxygen use anytime during the day (including, but not limited to, use only during activity, use only at night or use all day) * Tobacco use (including cigarettes, cigar, pipe, or vaping) or inhaled cannabis in the past 6 months * Current consumption of \> 14 alcoholic drinks per week * History of substance abuse including cocaine, methamphetamine, opioids, or narcotics; any use of cannabis * Uncontrolled diabetes, noncompliant with treatment or fasting glucose \> 250 mg/dL * Cancer: Stage 1 cancer (including melanoma skin cancers) within the past 5 years, other than adequately treated (fully excised and recovered from surgery based on the judgement of a study MD) basal and/or squamous cell skin cancer, or stage 2 or stage 3 cancer within 10 years, or any history of stage 4 (metastatic) cancer * Inability to get a normal systolic blood pressure reading (between 100-180) at two consecutive visits prior to randomization (must be at least 1 day apart) * ALT, AST, or Total Bilirubin \> Upper Limit of Normal (ULN) * Absolute Neutrophil Count outside normal range or \< 1.5 x109/L * White Blood Count outside normal range * Platelet count outside normal range or \< 125 x109/L * Hemoglobin \<10 g/dL * Total Cholesterol \> 300 mg/dL or Triglycerides \> 400 mg/dL * Dialysis treatment or chronic renal insufficiency defined as CKD-EPI eGFR \< 25 ml/min/(1.73) m2 * History of diverticular disease or GI perforation * History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies * Current use of Warfarin (Coumadin, Jantoven) * Unable or unwilling to provide informed consent * Current participation in another interventional study (including trials of exercise, diet, or investigational drugs) * A psychiatric disorder that is impairing ability to consent or comply with requirements of the trial * Residence or travel outside of the study area for more than one month during the study or planning to move out of the area in the next six months. * Other conditions which at the discretion of a study physician investigator which would make participation unsafe or inappropriate (logistic, behavioral, medical)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Frailty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Frailty Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pittsburgh, Health Studies Research Center

    Pittsburgh, Pennsylvania, 15260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.